Evaluating machine learning algorithms at predicting developmental trajectories using sequential dataset truncation of voluntary alcohol consumption in adolescent mice. [PDF]
Yu N, Buyske S, Qureshi U, Yu L.
europepmc +1 more source
Cellular ageing monographs in developmental biology, vol. 17 [PDF]
openaire +1 more source
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu +3 more
wiley +1 more source
From Conception to Birth: Bridging Embryonic Development and Disease. [PDF]
Theotokis P, Meditskou S, Manthou ME.
europepmc +1 more source
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant +11 more
wiley +1 more source
Modeling gliomas with organoids: reconstructing the human neural microenvironment for translational neuro-oncology. [PDF]
Ishan M, Jimenez-Macias JL, Read RD.
europepmc +1 more source
CEACAM1 participation in breast cancer progression
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin +3 more
wiley +1 more source
The notochord: development, disease and stem cell-based modelling. [PDF]
Warin J +4 more
europepmc +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
Glioblastoma Stem Cells as Targets for Emerging Precision Immunotherapies and Molecular Treatments. [PDF]
Steindler DA, Karakoula K.
europepmc +1 more source

